Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bemnifosbuvir/Ruzasvir and Ethinyl Estradiol/Levonorgestrel Drug-Drug Interaction Study
NCT07272889Phase 1Completed
- Sponsor
- Atea Pharmaceuticals
- Start
- Dec 2025
- Primary completion
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of bemnifosbuvir and ruzasvir in hepatitis C (HCV) (3 arms), sponsored by Atea Pharmaceuticals. Primary endpoints: Maximum Observed Plasma Concentration at Day 15 and Area Under the Plasma Concentration-Time Curve at Day 15. Started Dec 2025; status: completed.
02
Drugs
bemnifosbuvirruzasvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT07272889.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07272889.